干扰素目前已公认是临床治疗有效的“生物反应改变因子”。自1972年Karolinska开始临床研究,并首次临床应用白细胞干扰素治疗骨肉瘤以来,干扰素现已为临床公认的适应证有:毛细胞白血病、慢性粒细胞性白血病、卡波济肉瘤、尖锐湿疣及某些其他病毒性感染疾病等。近几年来有关干扰素的研究有不少报道,本文仅就干扰素的某些实验研究及相关临床的研究进展略作概述。一、干扰素的实验研究 (一)干扰素的类型和药理特性目前已被识别的干扰素有(α、β和γ)三种类型。-干扰素和β-干扰素具有相似的药理特性(表一);如皆有同样的细胞表面受体,但γ-干扰素则是一种不同的分子,具有更强的免疫调节作用。所有类型的干扰素具有共同特性——抗病毒活性,通过抑制病毒的RNA Interferon is now recognized as a “biological response modifying factor” effective in clinical treatment. Since Karolinska began clinical research in 1972, and the first clinical application of leukocyte interferon for the treatment of osteosarcoma, interferon has now been accepted as clinically accepted indications: hairy cell leukemia, chronic myelocytic leukemia, Kaposi’s sarcoma, condyloma acuminatum and Some other viral infections and so on. In recent years, there have been many reports on interferon studies. This article only briefly outlines some experimental studies of interferon and related clinical research progress. I. Experimental Study of Interferon (I) Types and Pharmacological Characteristics of Interferon There are currently three types of interferons (alpha, beta, and gamma) that have been identified. - Interferon and β-interferon have similar pharmacological properties (Table 1); if all have the same cell surface receptors, γ-interferon is a different molecule and has a stronger immunomodulatory effect. All types of interferons have common properties - antiviral activity, by inhibiting viral RNA